Exousia Pro, Inc. Revolutionizes Nutraceuticals With Launch Of Maxasome(TM): The First All-Natural, Biologically Active Exosomal Supplement

Rhea-AI Summary

Exousia Pro (OTCID:MAJI) announced on December 5, 2025 the market launch of Maxasome™, described as the first all-natural exosomal nutraceutical derived from 100% pure Exosome-Like Nanoparticles (ELNs) from Yellow Oyster Mushroom (Pleurotus citrinopileatus).

Maxasome™ is offered by monthly subscription at an estimated $200 for a 30-day supply and is positioned for telehealth and clinic partnerships targeting the longevity and wellness market that the company says spends over $100 million annually. The formulation claims a multi-modal biologically active payload including Ergothioneine, Beta-glucans, terpenoids, phenolics, and vitamin D2, and is available in sublingual, nasal, and enteric capsule delivery formats.

Positive

• Launch date December 5, 2025
• Price $200 per 30-day supply (estimated)
• Source ELNs from Yellow Oyster Mushroom (Pleurotus citrinopileatus)
• Payload Includes Ergothioneine, Beta-glucans, terpenoids, phenolics, Vitamin D2
• Delivery formats Sublingual, nasal inhalant, enteric-coated capsules
• Business model Monthly subscription for recurring revenue

Negative

• None.

News Market Reaction

+0.17%

1 alert

+0.17% News Effect

On the day this news was published, MAJI gained 0.17%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Maxasome price: $200 Target client spend: $100 million LMMY stake: 51% +5 more

8 metrics

Maxasome price $200 Estimated price for a 30-day supply subscription

Target client spend $100 million Annual spend by telehealth and clinic longevity clients

LMMY stake 51% Restricted common stock of LMMY obtained in all-stock transaction

Authorized shares 100,000,000 Post-transaction authorized share count for MAJI

Unrestricted float 2,527,000 Post-transaction unrestricted float shares

Fully diluted float 7,777,000 Includes 5,250,000 restricted shares losing restrictions in Q1 2026

Saliva volume 2 ml Sample volume for NANOG multi-cancer saliva screening test

Preclinical ODD rate 11% Share of Orphan Drug Designations awarded at preclinical stage

Market Reality Check

Price: $0.0524 Vol: Volume 57,722 is at 0.19x...

low vol

$0.0524 Last Close

Volume Volume 57,722 is at 0.19x the 20-day average of 304,851, indicating muted trading interest pre-news. low

Technical Shares at 0.049 are trading below the 200-day MA of 0.12, reflecting a longer-term downtrend before this launch.

Peers on Argus

While MAJI was down 16.13%, peers like CBIH (+25%), CVSI (+3.31%), and RVVTF (+0...

While MAJI was down 16.13%, peers like CBIH (+25%), CVSI (+3.31%), and RVVTF (+0.53%) showed mostly positive or flat moves, suggesting stock-specific pressure rather than a sector-wide move.

Historical Context

5 past events · Latest: Dec 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 05	Product launch	Positive	+0.2%	Launch of Maxasome™ exosomal nutraceutical with subscription pricing and partnerships focus.
Dec 02	Licensing deal	Positive	+33.3%	Exclusive license from UCF for exosome cancer diagnostic and therapy platforms worldwide.
Nov 17	Strategic acquisition	Positive	-44.2%	All-stock acquisition of controlling stake in LMMY and exosome tech licensing arrangement.
Nov 04	Technical milestone	Positive	+3.5%	CBD-loaded milk exosomes milestone with planned IRB study on bioavailability.
Oct 28	Regulatory designation	Positive	+9.1%	FDA Orphan Drug Designation for exosome-based GBM treatment filed by Exousia AI.

Pattern Detected

Recent MAJI headlines have generally seen price moves align with positive news, except for a sharp selloff following the strategic acquisition on Nov 17, 2025, indicating occasional divergence on complex corporate actions.

Recent Company History

Over the past few months, Exousia Pro has advanced its exosome platform through multiple milestones. On Oct 28, 2025, it received FDA Orphan Drug Designation for a GBM therapy, followed by a CBD exosome delivery breakthrough on Nov 4. A strategic realignment and majority stake acquisition in LMMY occurred on Nov 17, then an exosome cancer diagnostic licensing deal on Dec 2. Today’s Dec 5 Maxasome™ launch extends this trajectory into a commercial nutraceutical product.

Market Pulse Summary

This announcement marks the commercial debut of Maxasome™, an exosome-based nutraceutical derived fr...

Analysis

This announcement marks the commercial debut of Maxasome™, an exosome-based nutraceutical derived from mushroom Exosome-Like Nanoparticles and priced at an estimated $200 for a 30-day subscription. It complements earlier platform milestones, including an FDA Orphan Drug Designation and exosome delivery breakthroughs. Investors may focus on adoption within the telehealth and longevity markets that reportedly spend over $100 million annually, and on how this product integrates with the broader exosome diagnostics and therapeutics strategy.

Key Terms

exosome-like nanoparticles, cytoprotective, nanovesicles, beta-glucans, +4 more

8 terms

exosome-like nanoparticles medical

"Derived exclusively from 100% pure Exosome-Like Nanoparticles (ELNs) extracted..."

Exosome-like nanoparticles are tiny, cell-derived particles that act like microscopic delivery packages, carrying molecules such as drugs, RNA, or proteins between cells. Investors care because they can enable targeted therapies and more precise diagnostics—think of them as biological FedEx vans that can improve a drug’s effectiveness and reduce side effects—so success in developing or regulating these particles can materially affect a biotech company’s prospects and valuation.

cytoprotective medical

"an unprecedented, all-natural, multi-modal cytoprotective agent designed to deliver..."

Cytoprotective describes a drug, therapy, or substance that helps protect cells from injury, stress, or death caused by toxins, inflammation, lack of oxygen, or other damaging factors. For investors, cytoprotective effects can signal treatments that reduce side effects, improve patient outcomes, or expand a drug’s market by protecting healthy tissue during disease or therapy—similar to a protective coating that prevents wear and lets a product last longer under tough conditions.

nanovesicles medical

"These nanovesicles shield critical molecules from the harsh environment..."

Nanovesicles are tiny, cell-sized or smaller membrane-bound particles that carry molecules such as drugs, proteins or genetic material and can be made by cells or manufactured synthetically. Think of them as microscopic delivery trucks that can ferry therapeutic or diagnostic payloads to specific tissues or cells. Investors pay attention because successful use of nanovesicles can improve drug effectiveness, reduce side effects, speed development timelines, and create new commercial opportunities — but they also bring technical, regulatory and manufacturing risks.

beta-glucans medical

"including but not limited to Ergothioneine..., Beta-glucans, Terpenoids, Phenolic Compounds..."

Beta-glucans are naturally occurring fibers found in sources like oats, barley, yeast and certain mushrooms that can modulate immune responses and help lower cholesterol. They matter to investors because clinical evidence, regulatory status, and consumer demand determine whether products containing beta-glucans can be marketed, reimbursed, or scaled — similar to how a recipe ingredient can make or break a food product’s market success.

terpenoids medical

"Ergothioneine..., Beta-glucans, Terpenoids, Phenolic Compounds, and Vitamin D2."

Terpenoids are a large family of natural chemical compounds made by plants and some microbes that give fruits, herbs and flowers their smells, flavors and many of their effects; think of them as the ‘spices’ and essential oils that color a product’s scent and subtle influence. For investors, terpenoids matter because they shape product appeal, support different uses (aroma, flavor, therapeutic claims), affect regulatory review and labeling, and can create points of differentiation or intellectual property in consumer and pharmaceutical markets.

sublingual tincture medical

"including a sublingual tincture (oral drops held under the tongue)..."

A sublingual tincture is a liquid extract of a drug or botanical placed under the tongue so the active ingredients absorb directly into the bloodstream through the skin there. For investors, it matters because this delivery method typically gives faster and more consistent effects than swallowing a pill or edible, which can influence consumer preference, product pricing, regulatory labeling, shelf-stability and the competitive landscape in health and cannabis product markets.

enteric-coated capsules medical

"or encapsulated in enteric-coated capsules to ensure survival against stomach acid."

Enteric-coated capsules are pills with a special outer layer that prevents the medicine from dissolving in the acidic stomach and instead lets it release in the gentler environment of the intestines. For investors, this matters because the coating can improve a drug’s effectiveness, reduce side effects, extend patent or product differentiation, and add manufacturing or regulatory complexity that affects cost, timeline and market potential.

glp-1 medical

"compounds, such as GLP-1 and Testosterone therapies."

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

AI-generated analysis. Not financial advice.

ORLANDO, FLORIDA / ACCESS Newswire / December 5, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company leveraging proprietary exosome-based delivery systems, today announced the highly anticipated market launch of its flagship nutraceutical, Maxasome^™. Derived exclusively from 100% pure Exosome-Like Nanoparticles (ELNs) extracted from the high-value Yellow Oyster Mushroom (Pleurotus citrinopileatus), Maxasome^™ is an unprecedented, all-natural, multi-modal cytoprotective agent designed to deliver unparalleled cellular defense and extend health span.

The product will be offered to consumers on a monthly subscription basis, aligning with Exousia Pro's strategy to build recurring revenue within the high-growth longevity and wellness market.

Scientific Breakthrough: Engineering the Next-Generation Natural Exosomal Formulation

Maxasome^™ constitutes significant physiological advantages over conventional supplements, which are often limited by synthetic origins, poor oral absorption, and degradation within the gastrointestinal tract. Exousia Pro has engineered a solution that capitalizes on nature's most efficient delivery system:

• 100% Pure Exosomal Delivery: Maxasome^™ is the first supplement to encapsulate its bioactive payload entirely within naturally derived ELNs from P. citrinopileatus. These nanovesicles shield critical molecules from the harsh environment of the digestive system, ensuring enhanced bioavailability and targeted systemic uptake.

• Biologically Active Multi-Modal Payload: The formulation delivers a potent spectrum of anti-inflammatory and regenerative molecules, including but not limited to Ergothioneine (the "master antioxidant"), Beta-glucans, Terpenoids, Phenolic Compounds, and Vitamin D2. This comprehensive payload enables synergistic activity focused on:

  • Anti-Aging and Cellular Defense: Maximizing mitochondrial function and reducing DNA-damaging oxidative stress.

  • Skin and Tissue Regeneration: Supporting hydration, stimulating collagen production, and enhancing wound healing mechanisms.

• Versatile and Efficient Administration: Leveraging the company's nanoscale production technology, Maxasome^™ can be delivered via multiple efficient pathways, including a sublingual tincture (oral drops held under the tongue), as a nasal inhalant, or encapsulated in enteric-coated capsules to ensure survival against stomach acid.

Strategic Market Positioning and Growth

Maxasome^™ is strategically positioned to capture significant market share in the premium wellness sector. Exousia Pro plans to execute a targeted partnership strategy focused on telehealth networks and clinics that market high-value anti-aging and regenerative compounds, such as GLP-1 and Testosterone therapies. This approach allows Maxasome^™ to serve as a high-margin, complementary add-on product to a captive client base that spends over $100 million annually on advanced life-extension treatments. Maxasome^™ will be offered at an estimated price of $200 for a 30-day supply.

"The launch of Maxasome^™ is a pivotal inflection point for Exousia Pro, marking the successful commercialization of our proprietary exosome delivery technology into a tangible health solution," stated Matt Dwyer, President of Exousia Pro, Inc. "We have engineered a product that delivers the unmatched biopower of mushrooms in the most biologically relevant form-pure exosomes-offering consumers an unprecedented opportunity to reinforce their fundamental cellular defenses against aging. Maxasome^™ is set to become the foundational supplement for anyone serious about maximizing their healthspan and cognitive vitality."

About Exousia Pro, Inc.

Exousia Pro, Inc. (OTCID:MAJI), through its subsidiaries, is dedicated to developing and commercializing advanced exosome-based technologies. Our mission spans clinical-stage therapeutics, next-generation cancer diagnostics, and high-efficacy nutraceuticals, all centered on proprietary exosomal science and delivery systems.

SAFE HARBOR

Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Exousia Pro, Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Exousia Pro, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.

CONTACT:

Exousia Pro, Inc.
www.Exousiapro.com
X: @Exousia_Pro

Investor Relations
ir@exousiapro.com

SOURCE: Exousia Pro, Inc.

View the original press release on ACCESS Newswire

FAQ

What is Maxasome™ from Exousia Pro (MAJI) and when did it launch?

Maxasome™ is an all-natural exosomal nutraceutical from ELNs of Yellow Oyster Mushroom, launched December 5, 2025.

How much does Maxasome™ cost per month for MAJI customers?

Maxasome™ is offered at an estimated price of $200 for a 30-day supply on a monthly subscription.

What active ingredients does Maxasome™ (MAJI) advertise in its formulation?

The company lists Ergothioneine, Beta-glucans, terpenoids, phenolic compounds, and Vitamin D2 as key payload components.

Which delivery methods will Exousia Pro (MAJI) offer for Maxasome™?

Maxasome™ will be available as a sublingual tincture, a nasal inhalant, or in enteric-coated capsules.

How is Exousia Pro (MAJI) positioning Maxasome™ in the market?

The company targets premium longevity and wellness channels, pursuing telehealth and clinic partnerships as complementary add-on therapy.

What market opportunity does Exousia Pro (MAJI) cite for Maxasome™ distribution?

The company cites a captive client base that spends over $100 million annually on advanced life-extension treatments as a target opportunity.